POINT Biopharma Provides Update on Manufacturing, Supply Chain and Late-Stage Programs
Company’s radiopharmaceutical manufacturing facility now operational, supplying doses for the Phase 3 SPLASH trial – view the facility at manufacturing.pointbiopharma.com Will receive actinium-225 in 2022 from the US Department of Energy Isotope Program to support early-stage pipeline Dosimetry data from the lead-in cohort of the SPLASH trial in mCRPC will be published February 25th in…